Regina Kurrasch

708 total citations
21 papers, 534 citations indexed

About

Regina Kurrasch is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Regina Kurrasch has authored 21 papers receiving a total of 534 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Rheumatology, 12 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Immunology. Recurrent topics in Regina Kurrasch's work include Monoclonal and Polyclonal Antibodies Research (12 papers), Systemic Lupus Erythematosus Research (11 papers) and Rheumatoid Arthritis Research and Therapies (8 papers). Regina Kurrasch is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (12 papers), Systemic Lupus Erythematosus Research (11 papers) and Rheumatoid Arthritis Research and Therapies (8 papers). Regina Kurrasch collaborates with scholars based in United States, United Kingdom and Japan. Regina Kurrasch's co-authors include David J. Chang, Emilia Quattrocchi, Peter C. Taylor, Stephen Mallett, Jørgen Holm Petersen, Myron Chu, Paul P. Tak, Yoshiya Tanaka, Philip C. Fox and Daniel Aletaha and has published in prestigious journals such as The Lancet, The Journal of Immunology and PLoS ONE.

In The Last Decade

Regina Kurrasch

21 papers receiving 521 citations

Peers

Countries citing papers authored by Regina Kurrasch

Since Specialization

Citations

This map shows the geographic impact of Regina Kurrasch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Regina Kurrasch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Regina Kurrasch more than expected).

Fields of papers citing papers by Regina Kurrasch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Regina Kurrasch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Regina Kurrasch. The network helps show where Regina Kurrasch may publish in the future.

Co-authorship network of co-authors of Regina Kurrasch

This figure shows the co-authorship network connecting the top 25 collaborators of Regina Kurrasch. A scholar is included among the top collaborators of Regina Kurrasch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Regina Kurrasch. Regina Kurrasch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study 2022 ·Arthritis Research & Therapy ·Sang‐Cheol Bae, Damon Bass, Myron Chu, Paula Curtis, (unknown), (unknown), Beulah Ji, Regina Kurrasch, Saima Muzaffar, (unknown), David A. Roth, Yeong Wook Song, (unknown), Fengchun Zhang	8
2	Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses 2022 ·Modern Rheumatology ·Jie Zheng, Jieruo Gu, Yin Su, Yang Li, Xingfu Li, (unknown), Hua Cao, (unknown), Myron Chu, Paula Curtis, (unknown), Regina Kurrasch, (unknown), David A. Roth, Fengchun Zhang	4
3	Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea 2021 ·RMD Open ·Yoshiya Tanaka, Sang‐Cheol Bae, Damon Bass, Paula Curtis, Myron Chu, (unknown), Beulah Ji, Regina Kurrasch, (unknown), (unknown), David A. Roth	18
4	AB0288 SAFETY OF BELIMUMAB IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: YEAR 2 FOLLOW-UP OF A LARGE PHASE 4, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY 2021 ·Annals of the Rheumatic Diseases ·(unknown), Morton Scheinberg, James Cheng‐Chung Wei, Dana Tegzová, William Stohl, Tamara Mucenic, (unknown), Regina Kurrasch, Julia Harris, Saima Muzaffar, (unknown), N. L. Fox, (unknown), (unknown), David A. Roth	1
5	Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study 2021 ·Modern Rheumatology ·Yoshiya Tanaka, Paula Curtis, (unknown), Regina Kurrasch, Kyoko Kinoshita, Rika Tanaka, (unknown), David A. Roth	5
6	A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis 2020 ·Rheumatology and Therapy ·Wolfgang Schmidt, Bhaskar Dasgupta, Raashid Luqmani, Sebastian Unizony, Daniël Blockmans, Zhihong Lai, Regina Kurrasch, (unknown), Kurt Brown, Ravi Rao	36
7	Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study 2018 ·Annals of the Rheumatic Diseases ·Peter C. Taylor, Michael Schiff, Qingmin Wang, (unknown), Yanli Zhuang, Regina Kurrasch, Shruti Daga, Ravi Rao, Paul P. Tak, Benjamin Hsu	19
8	Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study 2018 ·RMD Open ·Carter Thorne, Tsutomu Takeuchi, George Karpouzas, Shihong Sheng, Regina Kurrasch, Kaiyin Fei, Benjamin Hsu	9
9	Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study 2017 ·The Lancet ·Daniel Aletaha, Clifton O. Bingham, Yoshiya Tanaka, Prasheen Agarwal, Regina Kurrasch, Paul P. Tak, (unknown)	82
10	Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials 2016 ·PLoS ONE ·Emilia Quattrocchi, Mikkel Østergaard, Peter C. Taylor, Ronald van Vollenhoven, Myron Chu, Stephen Mallett, (unknown), Regina Kurrasch	18
11	SAT0158 Response and Radiographic Progression in Biologic-Naïve and Biologic-Experienced Patients with Rheumatoid Arthritis Treated with Sirukumab 2016 ·Annals of the Rheumatic Diseases ·Carter Thorne, George Karpouzas, Tsutomu Takeuchi, (unknown), W. Xu, (unknown), Regina Kurrasch, (unknown), Benjamin Hsu	2
12	Epidemiology and Treatment of New‐Onset and Established Rheumatoid Arthritis in an Insured US Population 2015 ·Arthritis Care & Research ·Martin M. Crane, Maneesh Juneja, Jeffery K. Allen, Regina Kurrasch, Myron Chu, Emilia Quattrocchi, Stephanie Manson, David J. Chang	42
13	Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics 2013 ·The Journal of Rheumatology ·Regina Kurrasch, Judith C. Brown, Myron Chu, Jenny Craigen, Philip Overend, Bela Patel, Steven G. Wolfe, David J. Chang	34
14	Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial 2011 ·Annals of the Rheumatic Diseases ·Peter C. Taylor, Emilia Quattrocchi, Stephen Mallett, Regina Kurrasch, Jørgen Holm Petersen, David J. Chang	90
15	Kinetic analysis of muscarinic receptors in human brain and salivary gland in vivo 1995 ·American Journal of Physiology-Regulatory, Integrative and Comparative Physiology ·(unknown), W.C. Eckelman, Jorge A. Carrasquillo, Robert S. Miletich, Ingrid H. Valdez, Regina Kurrasch, (unknown), Chang H. Paik, Ronald D. Neumann, Bruce J. Baum	4
16	Effect of tumor necrosis factor‐α and interferon‐γ on the growth of a human salivary gland cell line 1994 ·Journal of Cellular Physiology ·Ava J. Wu, Regina Kurrasch, Joseph Katz, Philip C. Fox, (unknown), Jane C. Atkinson	43
17	Prednisone and piroxicam for treatment of primary Sjögren's syndrome. 1993 ·PubMed ·Philip C. Fox, Manuel B. Datiles, J. C. Atkinson, (unknown), J. T. Scott, Daniel J. Fletcher, Ingrid H. Valdez, Regina Kurrasch, Robert Delapenha, W. P. U. Jackson	73
18	Polymorphonuclear leukocytes cap a derivative of wheat germ agglutinin upon stimulation with formyl peptide and C5a but not leukotriene B4. 1989 ·The Journal of Immunology ·Regina Kurrasch, Fred Elfman, H. Daniel Perez	3
19	Characterization of a monoclonal antibody, OVB1, which binds to a unique determinant in human ovarian carcinomas and myeloid cells. 1989 ·Journal of Histochemistry & Cytochemistry ·Regina Kurrasch, A V Rutherford, Margaret E. Rick, (unknown), Elizabeth Lovelace, I Pastan, Mark C. Willingham	3
20	Capping of the surface OKT3 binding molecule prevents the T-cell proliferative response to antigens: Evidence that this molecule conveys the activation signal 1984 ·Cellular Immunology ·Gary M. Kammer, Regina Kurrasch, (unknown)	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact